Home > Research > Publications & Outputs > Localized nuclear reaction breaks boron drug ca...

Research

Links

Text available via DOI:

View graph of relations

Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy. / Shi, Yaxin; Guo, Zhibin; Fu, Qiang et al.
In: Nature Communications, Vol. 14, No. 1, 1884, 05.04.2023.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Shi, Y, Guo, Z, Fu, Q, Shen, X, Zhang, Z, Sun, W, Wang, J, Sun, J, Zhang, Z, Liu, T, Gu, Z & Liu, Z 2023, 'Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy', Nature Communications, vol. 14, no. 1, 1884. https://doi.org/10.1038/s41467-023-37253-x

APA

Shi, Y., Guo, Z., Fu, Q., Shen, X., Zhang, Z., Sun, W., Wang, J., Sun, J., Zhang, Z., Liu, T., Gu, Z., & Liu, Z. (2023). Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy. Nature Communications, 14(1), Article 1884. https://doi.org/10.1038/s41467-023-37253-x

Vancouver

Shi Y, Guo Z, Fu Q, Shen X, Zhang Z, Sun W et al. Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy. Nature Communications. 2023 Apr 5;14(1):1884. Epub 2023 Apr 5. doi: 10.1038/s41467-023-37253-x

Author

Shi, Yaxin ; Guo, Zhibin ; Fu, Qiang et al. / Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy. In: Nature Communications. 2023 ; Vol. 14, No. 1.

Bibtex

@article{52b4a774bb4440ca923bce660ef527a3,
title = "Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy",
abstract = "Boron neutron capture therapy (BNCT) was clinically approved in 2020 and exhibits remarkable tumour rejection in preclinical and clinical studies. It is binary radiotherapy that may selectively deposit two deadly high-energy particles (4He and 7Li) within a cancer cell. As a radiotherapy induced by localized nuclear reaction, few studies have reported its abscopal anti-tumour effect, which has limited its further clinical applications. Here, we engineer a neutron-activated boron capsule that synergizes BNCT and controlled immune adjuvants release to provoke a potent anti-tumour immune response. This study demonstrates that boron neutron capture nuclear reaction forms considerable defects in boron capsule that augments the drug release. The following single-cell sequencing unveils the fact and mechanism that BNCT heats anti-tumour immunity. In female mice tumour models, BNCT and the controlled drug release triggered by localized nuclear reaction causes nearly complete regression of both primary and distant tumour grafts.",
author = "Yaxin Shi and Zhibin Guo and Qiang Fu and Xinyuan Shen and Zhongming Zhang and Wenjia Sun and Jinqiang Wang and Junliang Sun and Zizhu Zhang and Tong Liu and Zhen Gu and Zhibo Liu",
year = "2023",
month = apr,
day = "5",
doi = "10.1038/s41467-023-37253-x",
language = "English",
volume = "14",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy

AU - Shi, Yaxin

AU - Guo, Zhibin

AU - Fu, Qiang

AU - Shen, Xinyuan

AU - Zhang, Zhongming

AU - Sun, Wenjia

AU - Wang, Jinqiang

AU - Sun, Junliang

AU - Zhang, Zizhu

AU - Liu, Tong

AU - Gu, Zhen

AU - Liu, Zhibo

PY - 2023/4/5

Y1 - 2023/4/5

N2 - Boron neutron capture therapy (BNCT) was clinically approved in 2020 and exhibits remarkable tumour rejection in preclinical and clinical studies. It is binary radiotherapy that may selectively deposit two deadly high-energy particles (4He and 7Li) within a cancer cell. As a radiotherapy induced by localized nuclear reaction, few studies have reported its abscopal anti-tumour effect, which has limited its further clinical applications. Here, we engineer a neutron-activated boron capsule that synergizes BNCT and controlled immune adjuvants release to provoke a potent anti-tumour immune response. This study demonstrates that boron neutron capture nuclear reaction forms considerable defects in boron capsule that augments the drug release. The following single-cell sequencing unveils the fact and mechanism that BNCT heats anti-tumour immunity. In female mice tumour models, BNCT and the controlled drug release triggered by localized nuclear reaction causes nearly complete regression of both primary and distant tumour grafts.

AB - Boron neutron capture therapy (BNCT) was clinically approved in 2020 and exhibits remarkable tumour rejection in preclinical and clinical studies. It is binary radiotherapy that may selectively deposit two deadly high-energy particles (4He and 7Li) within a cancer cell. As a radiotherapy induced by localized nuclear reaction, few studies have reported its abscopal anti-tumour effect, which has limited its further clinical applications. Here, we engineer a neutron-activated boron capsule that synergizes BNCT and controlled immune adjuvants release to provoke a potent anti-tumour immune response. This study demonstrates that boron neutron capture nuclear reaction forms considerable defects in boron capsule that augments the drug release. The following single-cell sequencing unveils the fact and mechanism that BNCT heats anti-tumour immunity. In female mice tumour models, BNCT and the controlled drug release triggered by localized nuclear reaction causes nearly complete regression of both primary and distant tumour grafts.

U2 - 10.1038/s41467-023-37253-x

DO - 10.1038/s41467-023-37253-x

M3 - Journal article

VL - 14

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1884

ER -